The National  Memo Logo

Smart. Sharp. Funny. Fearless.

Monday, December 09, 2019 {{ new Date().getDay() }}

New York (AFP) – Pharmaceutical giant Pfizer Tuesday announced that it settled patent litigation against Teva Pharmaceuticals over the sale of a generic version of blockbuster drug Viagra in the United States.

The settlement means Israel-based Teva “will be allowed to launch a generic version of Viagra in the U.S. on December 11, 2017 or earlier under certain circumstances,” Pfizer said in a statement.

“Teva will pay Pfizer a royalty for a license to produce its generic version,” Pfizer said.

Other terms of the agreement were confidential.

Patents for Viagra, which treats erectile dysfunction, expire in April 2020, Pfizer said.

In June 2010, Pfizer lost its patent in Brazil to exclusively sell the drug. Pfizer’s patent for Viagra has also expired in Europe and Japan.

The U.S. Food and Drug Administration has granted tentative approval for Teva’s generic version of Viagra, said Teva, which is the world’s biggest generic drug maker.

Photo: Waleed Alzuhair via Flickr

Start your day with National Memo Newsletter

Know first.

The opinions that matter. Delivered to your inbox every morning

ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

North Carolina state representative Mike Clampitt swore an oath to uphold the Constitution after his election in 2016 and again in 2020. But there's another pledge that Clampitt said he's upholding: to the Oath Keepers, a right-wing militant organization.

Keep reading... Show less

Reprinted with permission from DailyKos

When Donald Trump rolled out his brand new social media platform for deplorables, TRUTH Media, the clock started ticking on how soon it would crash and burn like Parler, Gab and other deplorable alternatives to Twitter.

Keep reading... Show less
x
{{ post.roar_specific_data.api_data.analytics }}